Top

Published in:

01-09-2015 | Co-infections and Comorbidity (S Naggie, Section Editor)

The Role of Viral Co-Infection in HIV-Associated Non-AIDS-Related Cancers

Authors: David J. Riedel, Lydia S. Tang, Anne F. Rositch

Published in: Current HIV/AIDS Reports | Issue 3/2015

Abstract

HIV-infected individuals are at increased risk for most types of cancer, including those typically classified as non-AIDS-defining cancers (NADCs). This increased risk is likely multifactorial, but a prominent risk factor for the increased rate of some cancers is co-infection with oncogenic viruses. Anal cancer, hepatocellular carcinoma, and Hodgkin lymphoma are three of the most common NADCs, and they are associated with co-infection with human papillomavirus, hepatitis B and C, and Epstein Barr virus, respectively. This review will examine the epidemiology, pathogenesis, and future trends around these virally associated NADCs frequently found in HIV-infected individuals.

Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384(9939):241–8. doi:10.1016/S0140-6736(14)60604-8.PubMed

Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 2014;28(8):1181–91.PubMed

Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, et al. Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. Clin Infect Dis. 2009;48(5):633–9.PubMed

Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50(10):1387–96. doi:10.1086/652283.

5.•

Deeken JF, Tjen ALA, Rudek MA, Okuliar C, Young M, Little RF, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis. 2012;55(9):1228–35. doi:10.1093/cid/cis613. This is a comprehensive overview of NADC epidemiology, etiology, screening, and treatment. It also takes note of the many areas where data is lacking and potential future research questions. PubMedCentralPubMed

Bruyand M, Ryom L, Shepherd L, Fatkenheuer G, Grulich A, Reiss P, et al. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study. J Acquir Immune Defic Syndr. 2015;68(5):568–77. doi:10.1097/QAI.0000000000000523.PubMed

7.•

Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009;23(17):2337–45. doi:10.1097/QAD.0b013e3283319184. This retrospective cohort study from the Kaiser Permanente population was the first to divide NADCs by their association with underlying infectious (predominantly viral) cause. The risk of infection-associated cancers was found to be most highly elevated. PubMedCentralPubMed

Lanoy E, Costagliola D, Engels EA. Skin cancers associated with HIV infection and solid-organ transplantation among elderly adults. Int J Cancer. 2010;126(7):1724–31. doi:10.1002/ijc.24931.PubMedCentralPubMed

Rositch AF, Nowak RG, Gravitt PE. Increased age and race-specific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000 to 2009. Cancer. 2014;120(13):2032–8. doi:10.1002/cncr.28548.PubMedCentralPubMed

10.

Bray F, Ren J-S, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133–45. doi:10.1002/ijc.27711.PubMed

11.

Riedel DJ, Mwangi EI, Fantry LE, Alexander C, Hossain MB, Pauza CD, et al. High cancer-related mortality in an urban, predominantly African-American. HIV-Infect Populat AIDS. 2013;27(7):1109–17. doi:10.1097/QAD.0b013e32835dc068.

12.

Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59–67. doi:10.1016/S0140-6736(07)61050-2.PubMed

13.

Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr. 2009;52(5):611–22. doi:10.1097/QAI.0b013e3181b327ca.PubMedCentralPubMed

14.

Silverberg MJ, Lau B, Justice AC, Engels E, Gill MJ, Goedert JJ, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. 2012;54(7):1026–34. doi:10.1093/cid/cir1012.PubMedCentralPubMed

15.

Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol. 2009;27(6):884–90. doi:10.1200/JCO.2008.19.6626.PubMed

16.

Piketty C, Selinger-Leneman H, Grabar S, Duvivier C, Bonmarchand M, Abramowitz L, et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS. 2008;22(10):1203–11. doi:10.1097/QAD.0b013e3283023f78.PubMed

17.

Seaberg EC, Wiley D, Martinez-Maza O, Chmiel JS, Kingsley L, Tang Y, et al. Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer. 2010;116(23):5507–16. doi:10.1002/cncr.25530.PubMedCentralPubMed

18.

Crum-Cianflone NF, Hullsiek KH, Marconi VC, Ganesan A, Weintrob A, Barthel RV, et al. Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS. 2010;24(4):535–43. doi:10.1097/QAD.0b013e328331f6e2.PubMedCentralPubMed

19.

Bertisch B, Franceschi S, Lise M, Vernazza P, Keiser O, Schoni-Affolter F, et al. Risk factors for anal cancer in persons infected with HIV: a nested case–control study in the Swiss HIV cohort study. Am J Epidemiol. 2013. doi:10.1093/aje/kwt153.

20.

Munoz-Bongrand N, Poghosyan T, Zohar S, Gerard L, Chirica M, Quero L, et al. Anal carcinoma in HIV-infected patients in the era of antiretroviral therapy: a comparative study. Dis Colon Rectum. 2011;54(6):729–35. doi:10.1007/DCR.0b013e3182137de9.PubMed

21.••

Marcus JL, Chao C, Leyden WA, Xu L, Yu J, Horberg MA, et al. Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers. Cancer Epidemiol Biomarkers Prev. 2015. doi:10.1158/1055-9965.EPI-14-1079. This retrospective cohort study from the Kaiser Permanente database compared survival in HIV-infected vs. uninfected patients after a NADC diagnosis. Cancer-related mortality for lung and prostate cancers was higher in the HIV-infected cohort compared with the HIV-uninfected cohort, but there was no difference for anal or colorectal cancer and Hodgkin lymphoma. PubMed

22.

Oehler-Janne C, Huguet F, Provencher S, Seifert B, Negretti L, Riener MO, et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol : Off J Am Soc Clin Oncol. 2008;26(15):2550–7. doi:10.1200/JCO.2007.15.2348.

23.

De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer J Int Cancer. 2009;124(7):1626–36. doi:10.1002/ijc.24116.

24.

Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer J Int Cancer. 2009;124(10):2375–83. doi:10.1002/ijc.24215.

25.

Steinau M, Unger ER, Hernandez BY, Goodman MT, Copeland G, Hopenhayn C, et al. Human papillomavirus prevalence in invasive anal cancers in the United States before vaccine introduction. J Lower Genit Tract Dis. 2013;17(4):397–403. doi:10.1097/LGT.0b013e31827ed372.

26.

Machalek DA, Poynten M, Jin F, Fairley CK, Farnsworth A, Garland SM. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol. 2012;13(5):487–500. doi:10.1016/S1470-2045(12)70080-3.PubMed

27.

de Pokomandy A, Rouleau D, Ghattas G, Vezina S, Cote P, Macleod J, et al. Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. J Infect Dis. 2009;199(7):965–73. doi:10.1086/597207.PubMed

28.

Conley L, Bush T, Darragh TM, Palefsky JM, Unger ER, Patel P, et al. Factors associated with prevalent abnormal anal cytology in a large cohort of HIV-infected adults in the United States. J Infect Dis. 2010;202(10):1567–76. doi:10.1086/656775.PubMed

29.

Critchlow CW, Hawes SE, Kuypers JM, Goldbaum GM, Holmes KK, Surawicz CM, et al. Effect of HIV infection on the natural history of anal human papillomavirus infection. AIDS. 1998;12(10):1177–84.PubMed

30.

Palefsky JM, Holly EA, Efirdc JT, Da Costa M, Jay N, Berry JM, et al. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. Aids. 2005;19(13):1407–14.PubMed

31.

Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97(6):425–32. doi:10.1093/jnci/dji072.PubMed

32.

Palefsky JM, Holly EA, Ralston ML, Da Costa M, Bonner H, Jay N, et al. Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection. J Acquir Immune Defic Syndr. 2001;28(5):422–8.PubMed

33.

Piketty C, Darragh TM, Heard I, Da Costa M, Bruneval P, Kazatchkine MD, et al. High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy. Sex Transm Dis. 2004;31(2):96–9. doi:10.1097/01.OLQ.0000109515.75864.2B.PubMed

34.

Centers for Disease C, Prevention. Human papillomavirus-associated cancers—United States, 2004–2008. MMWR Morb Mortal Wkly Rep. 2012;61:258–61.

35.

Wentzensen N, Follansbee S, Borgonovo S, Tokugawa D, Sahasrabuddhe VV, Chen J, et al. Analytic and clinical performance of cobas HPV testing in anal specimens from HIV-positive men who have sex with men. J Clin Microbiol. 2014;52(8):2892–7. doi:10.1128/jcm.03517-13.PubMedCentralPubMed

36.

Chiao EY, Giordano TP, Palefsky JM, Tyring S, El Serag H. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis : Off Public Infect Dis Soc Am. 2006;43(2):223–33. doi:10.1086/505219.

37.

Wentzensen N. Screening for anal cancer: endpoints needed. Lancet Oncol. 2012;13(5):438–40. doi:10.1016/S1470-2045(12)70101-8.PubMed

38.•

Ong JJ, Temple-Smith M, Chen M, Walker S, Grulich A, Hoy J, et al. Why are we not screening for anal cancer routinely—HIV physicians’ perspectives on anal cancer and its screening in HIV-positive men who have sex with men: a qualitative study. BMC Public Health. 2015;15:67. doi:10.1186/s12889-015-1430-1. This small Australian study described interviews from 20 HIV physicians and assessed attitudes toward anal cancer screening. Multiple barriers to screening were noted, and the providers were found to be ambivalent toward anal cancer screening. More research is clearly needed in this field. PubMedCentralPubMed

39.

Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis. 2010;10(12):845–52. doi:10.1016/s1473-3099(10)70219-x.PubMedCentralPubMed

40.

Lazenby GB, Unal ER, Andrews AL, Simpson K. A cost-effectiveness analysis of anal cancer screening in HIV-positive women. J Lower Genit Tract Dis. 2012;16(3):275–80. doi:10.1097/LGT.0b013e31823cde2f.

41.

Lam JM, Hoch JS, Tinmouth J, Sano M, Raboud J, Salit IE. Cost-effectiveness of screening for anal precancers in HIV-positive men. AIDS. 2011;25(5):635–42. doi:10.1097/QAD.0b013e3283434594.PubMed

42.

Palefsky JM, Giuliano AR, Goldstone S, Moreira Jr ED, Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576–85. doi:10.1056/NEJMoa1010971.PubMed

43.

Kojic EM, Kang M, Cespedes MS, Umbleja T, Godfrey C, Allen RT, et al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis. 2014;59(1):127–35. doi:10.1093/cid/ciu238.PubMedCentralPubMed

44.

Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis. 2010;202(8):1246–53. doi:10.1086/656320.PubMedCentralPubMed

45.

Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34(6):831–7. doi:10.1086/339042.PubMed

46.

Backus LI, Boothroyd D, Deyton LR. HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations. AIDS. 2005;19 Suppl 3:S13–9.PubMed

47.

Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis. 2003;188(4):571–7. doi:10.1086/377135.PubMed

48.

Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Putzolu V, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr. 2000;24(3):211–7.PubMed

49.

Salmon-Ceron D, Rosenthal E, Lewden C, Bouteloup V, May T, Burty C, et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French national Mortalité 2005 study. J Hepatol. 2009;50(4):736–45. doi:10.1016/j.jhep.2008.11.018.PubMed

50.

Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. AIDS. 2010;24(10):1537–48. doi:10.1097/QAD.0b013e32833a0918.PubMed

51.

Spaulding AC, Sharma A, Messina LC, Zlotorzynska M, Miller L, Binswanger IA. A comparison of liver disease mortality with HIV and overdose mortality among Georgia prisoners and releasees: a 2-decade cohort study of prisoners incarcerated in 1991. Am J Public Health. 2015;105(5):e51–7. doi:10.2105/AJPH.2014.302546.PubMed

52.••

Grint D, Peters L, Rockstroh JK, Rakmanova A, Trofimova T, Lacombe K, et al. Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals. AIDS. 2015. doi:10.1097/QAD.0000000000000674. This retrospective study from the EuroSIDA cohort found that liver-related deaths accounted for nearly 22% of all deaths in the HIV/HCV co-infected population. Risk factors for liver-related deaths included advanced fibrosis (≥ F2) and low CD4 count. The authors suggested that directly acting antivirals for HCV treatment should be prioritized for all patients with ≥ F2 fibrosis. PubMed

53.

Simonetti RG, Cammà C, Fiorello F, Politi F, D’Amico G, Pagliaro L. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci. 1991;36(7):962–72.PubMed

54.

Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol. 2014;61(1 Suppl):S79–90. doi:10.1016/j.jhep.2014.07.010.PubMedCentralPubMed

55.

Clifford GM, Rickenbach M, Polesel J, Dal Maso L, Steffen I, Ledergerber B, et al. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS. 2008;22(16):2135–41. doi:10.1097/QAD.0b013e32831103ad.PubMed

56.

Yanik EL, Napravnik S, Cole SR, Achenbach CJ, Gopal S, Dittmer DP, et al. Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence. AIDS. 2014;28(7):979–87. doi:10.1097/QAD.0000000000000167.PubMedCentralPubMed

57.

Kramer JR, Giordano TP, Souchek J, Richardson P, Hwang LY, El-Serag HB. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol. 2005;100(1):56–63. doi:10.1111/j.1572-0241.2005.40670.x.PubMed

58.

García-García JA, Romero-Gómez M, Girón-González JA, Rivera-Irigoin R, Torre-Cisneros J, Montero JL, et al. Incidence of and factors associated with hepatocellular carcinoma among hepatitis C virus and human immunodeficiency virus coinfected patients with decompensated cirrhosis. AIDS Res Hum Retrovirus. 2006;22(12):1236–41. doi:10.1089/aid.2006.22.1236.

59.

Giordano TP, Kramer JR, Souchek J, Richardson P, El-Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992–2001. Arch Intern Med. 2004;164(21):2349–54. doi:10.1001/archinte.164.21.2349.PubMed

60.

García-Samaniego J, Rodríguez M, Berenguer J, Rodríguez-Rosado R, Carbó J, Asensi V, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol. 2001;96(1):179–83. doi:10.1111/j.1572-0241.2001.03374.x.PubMed

61.

Bräu N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol. 2007;47(4):527–37. doi:10.1016/j.jhep.2007.06.010.PubMed

62.

Bourcier V, Winnock M, Ait Ahmed M, Sogni P, Pambrun E, Poizot-Martin I, et al. Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir). Clin Res Hepatol Gastroenterol. 2012;36(3):214–21. doi:10.1016/j.clinre.2011.11.002.PubMed

63.

Puoti M, Bruno R, Soriano V, Donato F, Gaeta GB, Quinzan GP, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS. 2004;18(17):2285–93.PubMed

64.

Soto B, Sánchez-Quijano A, Rodrigo L, del Olmo JA, García-Bengoechea M, Hernández-Quero J, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997;26(1):1–5.PubMed

65.

Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Multivirc Group Hepatol. 1999;30(4):1054–8. doi:10.1002/hep.510300409.

66.

Bonnard P, Lescure FX, Amiel C, Guiard-Schmid JB, Callard P, Gharakhanian S, et al. Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count. J Viral Hepat. 2007;14(11):806–11. doi:10.1111/j.1365-2893.2007.00874.x.PubMed

67.

Sulkowski MS, Mehta SH, Torbenson MS, Higgins Y, Brinkley SC, de Oca RM, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS. 2007;21(16):2209–16. doi:10.1097/QAD.0b013e3282f10de9.PubMed

68.

Martín-Carbonero L, Benhamou Y, Puoti M, Berenguer J, Mallolas J, Quereda C, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis. 2004;38(1):128–33. doi:10.1086/380130.PubMed

69.

Puoti M, Bonacini M, Spinetti A, Putzolu V, Govindarajan S, Zaltron S, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis. 2001;183(1):134–7. doi:10.1086/317644.PubMed

70.

Boyd A, Lasnier E, Molina JM, Lascoux-Combe C, Bonnard P, Miailhes P, et al. Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. Antivir Ther. 2010;15(7):963–74. doi:10.3851/IMP1649.PubMed

71.

Piroth L, Pol S, Miailhes P, Lacombe K, Lopes A, Fillion A, et al. Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study. Liver Int. 2015. doi:10.1111/liv.12777.

72.

Puoti M, Cozzi-Lepri A, Paraninfo G, Arici C, Moller NF, Lundgren JD, et al. Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. Antivir Ther. 2006;11(5):567–74.PubMed

73.

Bruyand M, Dabis F, Vandenhende MA, Lazaro E, Neau D, Leleux O, et al. HIV-induced immune deficiency is associated with a higher risk of hepatocarcinoma, ANRS CO3 Aquitaine Cohort, France, 1998–2008. J Hepatol. 2011;55(5):1058–62. doi:10.1016/j.jhep.2011.02.017.PubMed

74.

van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93. doi:10.1001/jama.2012.144878.PubMed

75.

Berenguer J, Alvarez-Pellicer J, Martin PM, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50(2):407–13. doi:10.1002/hep.23020.PubMed

76.

Limketkai BN, Mehta SH, Sutcliffe CG, Higgins YM, Torbenson MS, Brinkley SC, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA. 2012;308(4):370–8. doi:10.1001/jama.2012.7844.PubMed

77.

Yin J, Li N, Han Y, Xue J, Deng Y, Shi J, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol. 2013;31(29):3647–55. doi:10.1200/JCO.2012.48.5896.PubMed

78.

Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med. 2003;138(4):299–306.PubMed

79.

Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44(6):1543–54. doi:10.1002/hep.21415.PubMed

80.•

Giordano TP, Henderson L, Landgren O, Chiao EY, Kramer JR, El-Serag H, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007;297(18):2010–7. doi:10.1001/jama.297.18.2010.PubMed

81.

Omland LH, Farkas DK, Jepsen P, Obel N, Pedersen L. Hepatitis C virus infection and risk of cancer: a population-based cohort study. Clin Epidemiol. 2010;2:179–86.PubMedCentralPubMed

82.

Nyberg AH, Chung JW, Shi JM, Cheetham TC, Chiang KM, Haque R et al. Increased cancer rates in patients with chronic hepatitis C: an analysis of the cancer registry in a large U.S. health maintenance organization. 50th Annual Meeting of the European Association for the Study of the Liver; Vienna, Austria. 2015.

83.

Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103(9):753–62. doi:10.1093/jnci/djr076.PubMedCentralPubMed

84.

Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med. 2008;148(10):728–36.PubMed

85.•

Shiels MS, Koritzinsky EH, Clarke CA, Suneja G, Morton LM, Engels EA. Prevalence of HIV infection among U.S. Hodgkin lymphoma cases. Cancer Epidemiol Biomarkers Prev. 2014;23(2):274–81. doi:10.1158/1055-9965.EPI-13-0865. This SEER-based study found nearly 4% of US Hodgkin lymphoma cases were in HIV-infected individuals, a disproportionate number based on the US HIV prevalence (<1%). Additionally, the 5-year mortality in HIV-infected Hodgkin lymphoma cases was twice that of HIV-uninfected cases (37% vs. 18%). PubMedCentralPubMed

86.

Goedert JJ, Bower M. Impact of highly effective antiretroviral therapy on the risk for Hodgkin lymphoma among people with human immunodeficiency virus infection. Curr Opin Oncol. 2012;24(5):531–6. doi:10.1097/CCO.0b013e3283560697.PubMedCentralPubMed

87.

Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med. 2010;153(7):452–60. doi:10.1059/0003-4819-153-7-201010050-00008.PubMedCentralPubMed

88.

Lanoy E, Rosenberg PS, Fily F, Lascaux AS, Martinez V, Partisani M, et al. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. Blood. 2011;118(1):44–9. doi:10.1182/blood-2011-02-339275.PubMedCentralPubMed

89.

Yanik EL, Napravnik S, Cole SR, Achenbach CJ, Gopal S, Olshan A, et al. Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis. 2013;57(5):756–64. doi:10.1093/cid/cit369.PubMedCentralPubMed

90.••

Gopal S, Patel MR, Achenbach CJ, Yanik EL, Cole SR, Napravnik S, et al. Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort. Clin Infect Dis. 2014;59(2):279–86. doi:10.1093/cid/ciu270. This study integrating multiple US cohorts examined the timing of lymphoma diagnosis after ART initiation. 15% of Hodgkin cases met the definition for unmasking immune reconstitution inflammatory syndrome, signifying the importance of CD4 cells in the pathogenesis of the disease. PubMedCentralPubMed

91.

Carbone A, Gloghini A, Larocca LM, Antinori A, Falini B, Tirelli U, et al. Human immunodeficiency virus-associated Hodgkin’s disease derives from post-germinal center B cells. Blood. 1999;93(7):2319–26.PubMed

92.

Thompson LD, Fisher SI, Chu WS, Nelson A, Abbondanzo SL. HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases. Am J Clin Pathol. 2004;121(5):727–38. doi:10.1309/PNVQ-0PQG-XHVY-6L7G.PubMed

93.

Carbone A, Gloghini A, Serraino D, Spina M. HIV-associated Hodgkin lymphoma. Curr Opin HIV AIDS. 2009;4(1):3–10. doi:10.1097/COH.0b013e32831a722b.PubMed

94.

Engels EA. Non-AIDS-defining malignancies in HIV-infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities. AIDS. 2009;23(8):875–85. doi:10.1097/QAD.0b013e328329216a.PubMedCentralPubMed

95.

Dunleavy K, Wilson WH. How I treat HIV-associated lymphoma. Blood. 2012;119(14):3245–55. doi:10.1182/blood-2011-08-373738.PubMedCentralPubMed

96.

Tedeschi R, Bortolin MT, Bidoli E, Zanussi S, Pratesi C, Vaccher E, et al. Assessment of immunovirological features in HIV related non-Hodgkin lymphoma patients and their impact on outcome. J Clin Virol. 2012;53(4):297–301. doi:10.1016/j.jcv.2011.12.021.PubMed

97.•

Carbone A, Vaccher E, Gloghini A, Pantanowitz L, Abayomi A, de Paoli P, et al. Diagnosis and management of lymphomas and other cancers in HIV-infected patients. Nat Rev Clin Oncol. 2014;11(4):223–38. doi:10.1038/nrclinonc.2014.31. This in-depth review article discusses the association of viruses with HIV-related lymphomas along with the pathogenesis, molecular genetics, and virology. PubMed

98.

Bohlius J, Schmidlin K, Boue F, Fatkenheuer G, May M, Caro-Murillo AM, et al. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes. Blood. 2011;117(23):6100–8. doi:10.1182/blood-2010-08-301531.PubMed

99.

Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006;108(12):3786–91. doi:10.1182/blood-2006-05-024109.PubMedCentralPubMed

100.

Gloghini A, Carbone A. Why would the incidence of HIV-associated Hodgkin lymphoma increase in the setting of improved immunity? Int J Cancer. 2007;120(12):2753–4. doi:10.1002/ijc.22650.PubMed

101.

Clifford GM, Rickenbach M, Lise M, Dal Maso L, Battegay M, Bohlius J, et al. Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood. 2009;113(23):5737–42. doi:10.1182/blood-2009-02-204172.PubMed

102.

Clifford G, Franceschi S, Rickenbach M. Lymphocyte counts prior to Hodgkin lymphoma development response. Blood. 2009;114(11):2354–5. doi:10.1182/blood-2009-06-227264.

103.

Hoffmann C, Hentrich M, Gillor D, Behrens G, Jensen B, Stoehr A, et al. Hodgkin lymphoma is as common as non-Hodgkin lymphoma in HIV-positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study. HIV Med. 2015;16(4):261–4. doi:10.1111/hiv.12200.PubMed

Title: The Role of Viral Co-Infection in HIV-Associated Non-AIDS-Related Cancers
Authors: David J. Riedel
Lydia S. Tang
Anne F. Rositch
Publication date: 01-09-2015
Publisher: Springer US
Published in: Current HIV/AIDS Reports / Issue 3/2015
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-015-0276-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2015

Emerging Challenges in Managing Hepatitis B in HIV Patients

Eosinophilia in Patients Infected with Human Immunodeficiency Virus

Extrahepatic Manifestations of Hepatitis C Infection: Navigating CHASM

Erratum to: Southern Africa: the Highest Priority Region for HIV Prevention and Care Interventions

Acute HCV in HIV-Infected MSM: Modes of Acquisition, Liver Fibrosis, and Treatment

Treatment of Chronic HCV Genotype 1 Coinfection

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage